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Abstract
Introduction: Asthma is the most prevalent chronic disease in adults. It affects their quality of life. Studies confirm that depression 
and anxiety occurs in asthma patients.
Material and methods: The study involved 96 patients with asthma divided into two groups: patients with controlled (n = 33) 
and uncontrolled asthma (n = 63). The analysis of asthma control was performed on the basis of the ACT (Asthma Control Test) 
results. The study used SF-36 (Short Form 36) questionnaire and HADS (Hospital and Depression Scale) Scale.
Results: An analysis of the correlations between QoL (Quality of Life) and the level of depression revealed a decrease in QoL 
scores in MCS (Mental Component Score) domain in the group with controlled asthma (71.8 — patients without depression, 
53.4 — patients with probable depression, and 51.4 — patients with depression; p = 0.032). A similar analysis of the correla-
tions between QoL and the level of anxiety in this group of patients proved no correlations in PCS (Physical Component Score) 
and MCS domains. In the group of patients with uncontrolled asthma, anxiety and depression correlated negatively with the QoL 
in PCS and MCS domains. Anxiety and depression are found in asthma patients, with higher severity observed in patients with 
uncontrolled asthma. Female gender, the level of asthma control, asthma severity, smoking, as well as diagnoses of anxiety and 
depression are predictors of a significantly lower QoL in asthma.
Conclusions: Anxiety and depression are found in asthma patients, with higher severity observed in patients with uncontrolled 
asthma. Female gender, the level of asthma control, asthma severity, smoking, as well as diagnoses of anxiety and depression 
are predictors of a significantly lower quality of life in asthma.
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Introduction 
The Global Initiative for Asthma report — 
GINA 2006, has completely changed an approach 
to asthma treatment. It recommends the creation 
of education programs to fully control the disease. 
Effects of asthma therapy depend on patients’ 
readiness to cooperate with doctors and comply 
with their orders [1]. Scientific reports show that 
proper education of patients with bronchial asth-
ma not only increase the level of its control but 
also substantially improve perceived quality of 
life. In medical sciences underlines the importan-
ce of the Health Realated Quality of Life (HRQoL). 
The concept of HRQoL is created by Schipper et 
al. and it is defined as “functional effect of the 
disease and its treatment received by a patient” 
[2]. Measurement HRQoL in asthma patients is 
important. Understanding of factors affecting 
quality of life allows to schedule treatment plan. 
Patients’ education on asthma control is a mo-
difiable factor affecting quality of life [3]. Having 
a written Asthma Action Plan helps to decrease 
the number of asthmatic bouts and better control 
the disease. GINA recommends that such plans 
should be updated once a year [4]. 
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Asthma control is based on the estimation of 
the frequency and severity of symptoms. Patients 
should be able to assess the severity of symptoms 
over time, and know what factors cause the worse-
ning of their health status. It is also useful to keep 
an asthmatic diary and, in case of patients with 
severe asthma, to monitor PEF values every day 
[5]. Unfortunately, the Asthma Insight & Reality in 
Europe (AIRE) study, carried out in 29 countries 
in the world, demonstrated that less than five per 
cent of patients achieve full asthma control [6]. 
Efficient therapy for asthma includes the con-
trol of both daytime and night-time clinical symp-
toms, as well as the maintenance of normal life 
activity of a patient. Full asthma control means: 
the achievement of overall, current control, and 
thus reducing the risk of asthma exacerbations; 
the prevention of early loss of lung function; and 
no drug related side−effects [7]. 
Running a variable course and requiring perma-
nent health care, chronic asthma affects all aspects 
of patients’ activity. Available reports prove that 
patients with bronchial asthma have a low quality 
of life. Furthermore, many researchers assert that 
there is a relationship between mental state of asthma 
patients and symptoms of primary disease, its dyna-
mics, and treatment efficiency. In many cases, airway 
obstruction episodes are of emotional origin [8−10].
Co−existence of somatic and mental di-
sorders results in a more serious course of the 
disease and often more severe symptoms, while 
psychopathological factors (anxiety and depres-
sion) condition subjective feelings of patients. 
Numerous publications are available, which 
assess the quality of life of patients with bron-
chial asthma, while there are only few which 
describe how the level of asthma control affects 
quality of life and ability to deal with feelings of 
stress, frequently associated with asthma. In our 
study we just wanted to show that good control 
of asthma is not the only requirement for good 
clinical outcome, but improving the quality of 
life and reducing stress level are also important.
Material and methods
The study involved 96 patients with bron-
chial asthma treated in the Allergology Outpa-
tient Clinic of the Lower Silesian Centre of Lung 
Diseases in Wroclaw. 
The criteria for inclusion in the study were: 
asthma diagnosis, severity of symptoms, the 
level of symptom control determined according 
to the GINA guidelines of 2012, and 18 years of 
age or more.
The patients were divided into two groups: 
 — group C — patients with controlled asthma 
(n = 33) — results of the Asthma Control Test 
(ACT) ranging from 25 to 20 points 
 — group U — patients with uncontrolled 
asthma (n = 63) — the ACT results below 
20 points.
An analysis of asthma control was performed 
on the basis of the ACT results. Patients can obtain 
a maximum of 25 points, which is a score reflec-
ting full control of the disease. Scores of 24−20 
mean that asthma is well− but not fully−contro-
lled, and scores below 20 show that the disease 
is poorly controlled [11]. 
The quality of life was assessed with the 
Short Form−36 questionnaire (SF-36 ), which 
consists of 36 questions (items) concerning two 
aspects of quality of life: physical (Physical Com-
ponent Score, PCS) and mental (Mental Compo-
nent Score, MCS). In each category the score can 
range from 0 to 100 — the lower the score, the 
worse the quality of life [12]. 
The levels of anxiety and depression were 
determined using The Hospital Anxiety and De-
pression Scale (HADS). There are two subscales 
within this measure, each of them including 
seven statements related to the current emotio-
nal status. The scores are interpreted as follows: 
0−7 = normal levels of anxiety and depression; 
8−10 = borderline abnormal levels of anxiety 
and depression, and 11−21 = abnormal levels 
of anxiety and depression [13]. 
A statistical analysis of the results was per-
formed using STATISTICA 10 and an Excel 
spreadsheet.
The study described in the article was appro-
ved by the Bioethical Commission of the Medical 
University of Wroclaw (no. KB−154/2013). 
Results
A profile of asthma patients in relation to the 
level of symptom control is shown in Table 1. 
A clinical analysis proved that patients in 
group C were more often diagnosed as having 
intermittent asthma (27.3%) and chronic mild 
asthma (42.4%), while patients in group U had 
usually chronic moderate asthma (31.8%) and 
chronic severe asthma (34.9%). An average du-
ration of asthma was longer in group U (12.7 ± 
12.2 vs. 7.2 ± 9.4; p = 0.001). Over 30% of group 
U had night-time asthma symptoms several times 
a week. In group C, night-time asthma symptoms 
occurred rarer than once a month in 48.5% of 
patients. In group U, nearly 40% of patients were 
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Table 1. A profile of asthma patients in relation to the level of symptom control
Feature With controlled asthma
(C)
n = 33
With uncontrolled astma
(U)
n = 63
Comparison
C vs. U 
p
Gender:
Women
Men
19 (57.6%)
14 (42.4%)
41 (65.1%)
22 (34.9%)
0.618
Age [year of life]
mean ± SD 49.4 ± 18.5 58.0 ± 16.4
0.022
Education:
primary
vocational
secondary
higher 
3 (9.1%)
2 (6.1%)
16 (48.5%)
12 (36.4%)
13 (20.6%)
26 (41.3%)
18 (28.6%)
6 (9.5%)
< 0.001
Professional activity:
1. yes
2. no
18 (54.6%)
15 (45.4%)
14 (22.2%)
49 (77.8%)
0.003
Type of actual profession:
1. manual
2. non-manual
14 (42.4%)
19 (57.6%)
47 (74.6%)
16 (25.4%)
0.009
Type of asthma:
intermittent
chronic mild
chronic moderate
chronic severe
9 (27.3%)
14 (42.4%)
6 (18.2%)
4 (12.1%)
3 (4.8%)
18 (28.6%)
20 (31.8%)
22 (34.9%)
0.001
Smoking:
0. no
1. no more 
2. yes
27 (81.8%)
6 (18.2%)
0 (0.0%)
30 (47.6%)
24 (38.1%)
9 (14.3%)
0.003
Duration of smoking [years]
mean ± SD
median (min ± max)
 
1.9 ± 4.6
0 (0 ± 20)
6.2 ± 9.7
2 (0 ± 50)
0.007
Duration of the disease [years]
mean ± SD
median (min ± max)
7.2 ± 9.4
4 (1 ± 40)
12.7 ± 12.2
9 (1 ± 60)
0.001
How often do night-time asthma symptoms occur?
1. less than once a month and they are short-lived 
2. more than twice a month; they can disturb sleep and hin-
der daytime activity 
3. more than once a week 
4. 2−3 times a week or more 
16 (48.5%)
8 (24.2%)
7 (21.2%)
2 (6.1%)
18 (28.6%)
13 (20.6%)
12 (19.0%)
20 (31.8%)
0.043
The frequency of visits to the Allergology Outpatient 
Clinic:
1. once or twice a month 
2. six times a year 
3. three times a year 
4. rarer 
4 (12.1%)
9 (27.3%)
19 (57.6%)
1 (3.0%)
21 (33.4%)
13 (20.6%)
16 (25.4%)
13 (20.6%)
0.005
Stays in hospital due to asthma:
no stays 
1−2 times
3−5 times
6 or more times
13 (39.4%)
16 (48.4%)
2 (6.1%)
2 (6.1%)
5 (7.9%)
21 (33.3%)
12 (19.1%)
25 (39.7%)
< 0.001
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Table 2. Quality of life analysis performed with the SF-36 in relation to the level of asthma control 
The questionnaire  
domains
With controlled asthma
(C)
n = 33
With uncontrolled asthma
(U)
n = 58
Comparison
C vs. U 
p
PF
mean ± SD
median (min ± max)
64.7 ± 30.9
80 (0 ± 100)
39.0 ± 29.1
35 (0 ± 100)
< 0.001
RP
mean ± SD
median (min ± max)
50.8 ± 39.3
50 (0 ± 100)
30.2 ± 39.2
0 (0 ± 100)
0.015
BP
mean ± SD
median (min ± max)
64.1 ± 25.8
62 (10 ± 100)
46.4 ± 25.9
41 (0 ± 100)
0.001
VT
mean ± SD
median (min ± max)
56.1 ± 13.7
55 (35 ± 90)
43.5 ± 23.1
45 (0 ± 85)
0.014
GH
mean ± SD
median (min ± max)
43.9 ± 14.4
45 (10 ± 67)
36.1 ± 16.7
35 (0 ± 75)
0.013
SF
mean ± SD
median (min ± max)
66.7 ± 25.3
75 (0 ± 100)
48.4 ± 30.4
50 (0 ± 100)
0.004
RE
mean ± SD
median (min ± max)
62.6 ± 41.5
67 (0 ± 100)
52.9 ± 43.4
67 (0 ± 100)
0.296
MH
mean ± SD
median (min ± max)
64.8 ± 17.6
60 (32 ± 96)
56.5 ± 23.6
60 (12 ± 100)
0.133
PCS
mean ± SD
median (min ± max)
58.9 ± 21.1
61 (15 ± 94)
39.8 ± 22.7
38 (3 ± 91)
< 0.001
MCS
mean ± SD
median (min ± max)
59.5 ± 20.0
64 (25 ± 87)
48.5 ± 21.6
47 (10 ± 86)
0.023
PF — physical functioning; RP — role limitations due to physical problems; BP — bodily pain; GH — general health perception; VT — vitality; SF — social functioning; 
MH — mental health; RE — role limitation due to emotional problems
hospitalized due to asthma at least six times more 
frequently than in group C, and 33.4% visited the 
Allergology Outpatient Clinic even twice a month. 
A vast majority of patients in group C had not 
been hospitalized due to asthma (39.4%) or were 
in hospital only once or twice (48.8%).
The result analysis showed that women pre-
dominated in both groups: group U — 65.1% and 
group C — 57.6%, p = 0.618 (ns). Patients with 
uncontrolled asthma were also worse educated 
than those with controlled asthma (primary edu-
cation: 20.6% vs. 9.1% and vocational education: 
41.3% vs. 6.1%), and less professionally active 
(22.2% vs. 54.6%).
The analysis revealed that patients with 
controlled asthma had higher quality of life. The 
total quality of life score within the physical 
functioning (PCS) (consisting of the domains: PF, 
RP, BP, VT) was higher in group C than in group 
U 58.9 (SD 21.1) vs. 39.8 (SD 22.7) respectively. 
The difference between these values was statisti-
cally significant. The above values are shown in 
table 2. Also the total quality of life score within 
the mental functioning (MCS) (consisting of the 
domains: SF, RE, MH, GH) was higher in group 
C compared to group U (59.5 ± 20.0) vs. 48.5 
(± 21.6, respectively). The difference between 
these values was statistically significant. The 
above values are shown in Table 2.
The analysis of anxiety and depression per-
formed with the HADS demonstrated statistically 
significantly higher levels of anxiety (11.3 ± 4.4 
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Table 3. Analysis of anxiety and depression according to the HADS in relation to the level of asthma control 
Feature With controlled asthma
(C)
n = 33
With uncontrolled asthma
(U)
n = 58
Comparison
C vs. U
p
HADS results — Depression
mean ± SD
median (min ± max)
8.9 ± 4.5
9 (1 ± 19)
10.9 ± 4.8
10 (3 ± 20)
0.052
HADS results − Anxiety
mean ± SD
median (min ± max)
8.6 ± 4.7
8 (0 ± 20)
11.3 ± 4.4
11 (2 ± 20)
0.007
HADS results — depression:
no depression
probable depression 
definite depression
12 (36.4%)
11 (33.3%)
10 (30.3%)
14 (22.2%)
18 (28.6%)
31 (49.2%)
0.168
HADS results — anxiety:
no anxiety
probable anxiety
definite anxiety
13 (39.4%)
12 (36.4%)
8 (24.2%)
13 (20.6%)
17 (27.0%)
33 (52.4%)
0.024
HADS — Hospital and Depression Scale
Table 4. Analysis of a correlation between the quality of life score according to the SF-36 and the level of depression
HADS — diagnosis (C) Comparison 
P
No
depression
Probable
depression
Definite
depression
SF-36 PCS
mean ± SD
n = 12
68.2 ± 17.2
n = 11
46.0 ± 22.5
n = 10
61.9 ± 18.1
0.052
SF-36 MCS
mean ± SD
n = 12
71.8 ± 12.1
n = 11
53.4 ± 21.9
n = 10
51.4 ± 19.9
0.032
HADS — diagnosis (U) Comparison 
P
No
depression
Probable
depression
Definite  
depression 
SF-36 PCS
mean ± SD
n = 14
48.6 ± 25.0
n = 18
49.2 ± 21.7
n = 31
30.3 ± 18.5
0.003
SF-36 MCS
mean ± SD
n = 14
57.5 ± 20.9
n = 18
53.3 ± 20.9
n = 31
33.7 ± 18.2
0.002
HADS — Hospital and Depression Scale; SF-36 — Short Form 36; PCS — Physical Component Score; MCS — Mental Component Score
U vs. 8.6 ± 4.7 C; p = 0.007) in the group of 
patients with uncontrolled asthma. In the group 
with uncontrolled asthma definite anxiety was 
diagnosed in over a half of patients (52.4%), 
while in the group with controlled asthma only 
in 24.2%; p = 0.024 (Table 3).
The analysis of the correlations between qu-
ality of life measured with the SF-36 and the level 
of depression determined with the HADS revealed 
a decrease in quality of life scores in MCS domain 
in the group with controlled asthma (71.8 — pa-
tients without depression, 53.4 — patients with 
probable depression, and 51.4 — patients with 
definite depression; p = 0.032) (Table 4).
In the group with uncontrolled asthma, 
quality of life scores were lower both in PCS 
domain (48.6 — patients without depression, 
49.2 — patients with probable depression, 
and 30.3 — patients with definite depression; 
p = 0.003), and MCS domain (57.5 — patients 
without depression, 53.3 — patients with proba-
ble depression, and 33.7 — patients with definite 
depression; p = 0.002). It should be emphasized 
that patients with uncontrolled asthma and 
a diagnosis of definite depression obtained signi-
ficantly lower quality of life scores in both PCS 
and MCS domains than patients with controlled 
asthma (Table 4).
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Table 5. Analysis of a correlation between the quality of life score according to the SF-36 and the level of anxiety
HADS — diagnosis (C) Comparison
P
No
anxiety
Probable
anxiety
Definite
anxiety
SF-36 PCS
mean ± SD
n = 13
64.1 ± 15.1
n = 12
52.9 ± 27.2
n = 8
59.4 ± 19.1
0.629
SF-36 MCS
mean ± SD
n = 13
65.5 ± 16.1
n = 12
59.5 ± 23.7
n = 8
49.8 ± 18.1
0.237
HADS — diagnosis (U) Comparison
P
No
anxiety
Probable
anxiety
Definite  
anxiety
SF-36 PCS
mean ± SD
n = 13
54.8 ± 26.2
n = 17
45.6 ± 23.9
n = 33
30.8 ± 16.3
0.008
SF-36 MCS
mean ± SD
n = 13
62.7 ± 21.2
n = 17
53.2 ± 20.0
n = 33
40.5 ± 19.4
0.006
HADS — Hospital and Depression Scale; SF-36 — Short Form 36; PCS — Physical Component Score; MCS — Mental Component Score
The analysis of the correlations between the 
quality of life assessed with the SF-36 and the 
level of anxiety measured with the HADS showed 
that there was no correlation between the quality 
of life in PCS and MCS domains and the level of 
anxiety (Table 5).
In the group of patients with uncontrolled 
asthma, on the other hand, the quality of life was 
statistically significantly lower in PCS domain (no 
anxiety 54.8, probable anxiety 45.6, and definite 
anxiety 30.8; p = 0.008) and MCS domain (no 
anxiety 62.7, probable anxiety 53.2, and definite 
anxiety 40.5; p = 0.006) proportionally to the 
level of anxiety. It should be said that patients 
from group U with a diagnosis of definite anxiety 
according to the HADS had lower quality of life 
than those from group C (Table 5).
A one-factor quality of life analysis in rela-
tion to additional variables potentially having an 
influence on quality of life is shown in table 6. 
The statistically significant data (p < 0.05) were 
written with bold font. 
In the one-factor analysis, lower quality of 
life in PCS domain was noted in patients with 
uncontrolled asthma (39.8 ± 22.7 vs. 58.9 ± 21.1), 
women (41.8 ± 21.7 vs. 53.9 ± 25.6), patients 
with a diagnosis of chronic severe asthma (32.6 
± 20.6 vs. 63.8 ± 21.6), smokers (29.7 ± 23.1 vs. 
50.4 ± 23.3), physically inactive patients (37.7 ± 
26.8 vs. 52.3 ± 19.8), patients with a diagnosis of 
definite depression (38.0 ± 22.8 vs. 57.6 ± 23.6), 
and those with a diagnosis of definite anxiety 
(36.4 ± 20.2 vs. 59.5 ± 21.5) (Table 6).
The analysis revealed lower quality of life in 
MCS domain among patients with uncontrolled 
asthma (48.5 ± 21.6 vs. 59.5 ± 20.0), women (46.8 
± 20.9 vs. 61.4 ± 19.9), patients with a diagnosis of 
chronic severe asthma (42.8 ± 20.9 vs. 68.1 ± 18.6), 
patients with a diagnosis of definite depression (41.8 
± 19.2 vs. 64.1 ± 18.6), and those with a diagnosis of 
definite anxiety (42.3 ± 19.3 vs. 64.1 ± 18.5) (Table 6).
Discussion
Quality-of-life studies are a precious com-
plement to medical examination, especially in 
chronic diseases, which require total involvement 
of a patient in the therapeutic process. 
For its chronic and changeable course, bron-
chial asthma can affect patients’ general satis-
faction and quality of life. On the other hand, 
a number of factors contributing to satisfaction 
and quality of life may influence the course of 
the disease. Available reports show that despite 
modern treatment, full control of symptoms is 
not achieved in all patients [14−16].
It is essential to show a relationship between 
quality of life and other objective results of exa-
minations performed to evaluate functions of an 
organism and efficiency of the therapy. 
The study presented here confirmed that 
patients with uncontrolled asthma had lower qu-
ality of life according to the SF-36 questionnaire. 
They obtained lower scores for both physical and 
mental health. The relationship between asthma 
control and quality of life has been documented 
in literature [17−20].
Sousa [16] reported on a strong correlation 
between asthma control and quality of life. Factors 
which correlated with asthma control included: 
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Table 6. Mean scores of PCS and MCS domains in relation to baseline variables analyzed (one-factor analysis)
Qualitative factor SF-36 PCS
mean ± SD
SF-36 MCS
mean ± SD
Type of asthma:
controlled C (n = 33) 58.9 ± 21.1 59.5 ± 20.0
uncontrolled U (n = 63) 39.8 ± 22.7 48.5 ± 21.6
Mann-Whitney U test, a: p < 0.001 0.023
Gender:
women (n = 60) 41.8 ± 21.7 46.8 ± 20.9
men (n = 36) 53.9 ± 25.6 61.4 ± 19.9
Mann-Whitney U test, a: p 0.024 0.002
Asthma severity level:
intermittent (n = 12) 63.8 ± 21.6 68. ± 18.6
chronic mild (n = 32) 50.1 ± 22.5 57.3 ± 21.3
chronic moderate (n = 26) 47.4 ± 23.5 48.3 ± 19.0
chronic severe (n = 26) 32.6 ± 20.6 42.8 ± 20.9
Kruskal-Wallis test: p 0.001 0.003
Smoking:
no (n = 57) 50.4 ± 23.3 54.6 ± 21.3
no more (30) 43.6 ± 23.4 50.7 ± 19.6
yes (n = 9) 29.7 ± 23.1 42.5 ± 28.3
Kruskal-Wallis test: p 0.036 0.334
Physical activity:
no (n = 39) 37.7 ± 26.8 47.5 ± 24.5
yes (n = 57) 52.3 ± 19.8 55.5 ± 18.9
Mann-Whitney U test, p 0.001 0.112
HADS results — depression:
no diagnosis of depression (n = 26) 57.6 ± 23.6 64.1 ± 18.6
probable depression (n = 29) 48.0 ± 21.7 56.5 ± 21.0
definite depression (n = 41) 38.0 ± 22.8 41.8 ± 19.2
Kruskal-Wallis test: p 0.004 < 0.001
HADS results — anxiety:
no diagnosis of anxiety (n = 26) 59.5 ± 21.5 64.1 ± 18.5
probable anxiety (n = 29) 48.6 ± 25.1 55.8 ± 21.4
definite anxiety (n = 41) 36.4 ± 20.2 42.3 ± 19.3
Kruskal-Wallis test: p 0.001 < 0.001
HADS — Hospital and Depression Scale; SF-36 — Short Form 36; PCS — Physical Component Score; MCS — Mental Component Score
gender, co-existing diseases, respiratory efficien-
cy, and asthma severity. Furthermore, gender and 
severity of asthma were recognized in his study as 
predictors of a lower quality of life. In the study 
described in this article, one-factor analysis reve-
aled that both female gender and asthma severity 
were factors lowering quality of life in PCS and 
MCS domains. According to Laforest et al. [21] 
female gender, residence in a rural area, and 
a low level of education were predictors of a lower 
quality of life among asthma patients.
Findings of Federman et al. [22] show that 
there is a relationship between low health awa-
reness and poor asthma control, a higher number 
of visits to family practitioner, and more frequent 
hospitalizations. In the presented study, almost 
40% of patients with uncontrolled asthma had 
six or more stays in hospital due to asthma. At 
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the same time, they paid regular visits to the 
Allergology Outpatient Clinic definitely rarer than 
patients with controlled asthma. 
In the study conducted by Marinez-Mpra-
gon et al. [3] control of symptoms and educa-
tion on asthma self−control were mentioned 
as factors having substantial influence on 
asthma. In the presented one-factor analysis, 
uncontrolled asthma was a determinant signi-
ficantly lowering quality of life in PCS and 
MCS domains. 
Nogueira [23] claims that next to second−
hand smoking, taking drugs, and professional 
activity, the level of education is a statistically 
significant predictor of low asthma control and 
low quality of life. In the presented one-factor 
analysis, smoking was an important predictor of 
a lower quality of life in PCS domain.
In this study, the lower quality of life in the 
group of patients with uncontrolled asthma can 
be associated with their older age, a lower level 
of education, the lack of professional activity, and 
in a vast majority — a diagnosis of moderate and 
severe asthma. Moreover, patients with uncon-
trolled asthma suffered from asthma for a longer 
time, had more severe daytime and night-time 
symptoms, were more often hospitalized, and 
paid rarer visits to a specialist outpatient clinic. 
Patients with uncontrolled asthma were nearly 
10 years older than those with controlled asthma 
(average age 58 years). It has been demonstrated 
in our previous studies, that age over 50 years 
is a negative contributor to physical and men-
tal functioning of patients. The quality of life 
assessed with the SF-36 questionnaire revealed 
statistically significant differences compared to 
patients below 50 years of age [24]. 
In this study, the average duration of the 
disease in the group with uncontrolled asthma 
was 12.7 years, i.e. over five years more than 
in the group with controlled asthma. Our other 
studies showed that people who had asthma for 
over 10 years assessed their quality of life in the 
PF domain of the SF-36 considerably lower than 
those who did not suffer from this disease for 
such a long time [25]. 
One more factor reducing patients’ ability to 
comply with therapeutic recommendations, and 
lowering their quality of life is first- and second
-hand smoking [15, 23]. In the presented study, 
more than 14% of patients with uncontrolled 
asthma were heavy smokers and more than 38% 
gave up smoking. Emphasis should be given to 
the fact that smoking worsens control of asthma, 
makes its course more serious, and contributes to 
the necessity for more intensive pharmacological 
treatment [26]. 
In recent years, attention has been paid to the 
problem of symptom control in bronchial asthma. 
The concept of treatment efficiency assessment 
based on determination of the level of the disease 
control was included in the GINA guidelines. 
Classification of asthma severity grounded exc-
lusively on the frequency of symptoms and the 
assessment of functional respiratory parameters 
ignores many aspects which are important for 
patients and may substantially decrease their 
quality of life and the possibility of treatment. 
Somatic disease is a strong mental strain for 
patients. Stress caused by chronic disease and 
paroxysmal dyspnea results in emotional disor-
ders. Lower mood and extreme emotions may 
cause asthmatic bouts, which in turn increases 
anxiety [8, 10, 27]. Respiratory disorders in the 
course of bronchial asthma belong to physio-
logical mechanisms of depression and anxiety 
development [8, 28]. 
According to the outcomes of this study, 
depression occurred both in patients with con-
trolled and uncontrolled asthma, however the 
latter had more severe symptoms (10.9 vs. 8.9). 
Nevertheless, the differences were statistically 
insignificant. Anxiety measurement performed 
with the HADS revealed statistically significantly 
higher levels of anxiety in the group of patients 
with uncontrolled asthma (definite anxiety was 
diagnosed in over a half of the patients). 
Available reports confirm higher anxiety 
and depression levels in patients with severe 
symptoms and a serious course of asthma [29]. 
According to Lewandowska et al. [30], depression 
and anxiety syndromes are jointly responsible for 
the occurrence of acute dyspnea attacks.
The analysis of a correlation between de-
pression and quality of life proved a statistically 
significant correlation in MCS domain both in pa-
tients with controlled and uncontrolled asthma. A 
correlation between quality of life and depression 
in PCS domain was only found in patients with 
uncontrolled asthma. 
The analysis of a correlation between anxiety 
and quality of life also revealed a statistically 
significant correlation in PCS and MCS domains, 
but only in the group with uncontrolled asthma. 
It was observed that the quality of life in both 
domains was statistically significantly decreasing 
along with an increase in the level of anxiety. 
In the one-factor analysis, diagnoses of definite 
anxiety and depression negatively affected the 
quality of life in PCS and MCS domains.
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In their study on a group of 715 patients 
with bronchial asthma, aged 22−44 years, Le-
ander et al. [31] found a statistical correlation 
between anxiety and depression and the report 
of asthma symptoms, such as attacks of dyspnea 
after activity and waking with attacks of dyspnea. 
However, there was no significant correlation be-
tween anxiety or depression and a self-reported 
diagnosis of asthma or objective asthma-related 
variables, such as peak flow variability or re-
sponse to methacholine. When evaluating the 
combined influence of psychological factors and 
objective variables, the HADS correlated inde-
pendently with reported wheezing, waking with 
attacks of dyspnea, waking with chest tightness, 
attacks of dyspnea when at rest, and attacks of 
dyspnea after activity. The authors, however, did 
not analyze effects of the disease control on the 
levels of depression and anxiety. 
As evidenced by the study of Hasler et al. 
[32], severe asthma symptoms contribute to the 
occurrence of panic attacks. Other contributors 
mentioned by these authors are: age, anxiety, smo-
king, alcohol abuse, and family history of asthma. 
Feldman [33] confirmed a lower quality of 
life among people with mood disorders (panic 
attacks) irrespective of asthma severity, socio−
demographic factors, and respiratory efficiency.
Schneider et al. [34], on the other hand, 
proved that depression and not panic attacks 
is a factor which may have an influence on the 
assessment of quality of life by asthma patients. 
Likewise our results, findings of Kullowatz 
[35] confirmed effects of depression and anxiety 
on quality of life. In his study, anxiety was a factor 
negatively affecting quality of life in a psycholo-
gical domain, while depression lowered quality 
of life in both the physical and psychological 
domains. 
Available literature shows that patients with 
asthma more often suffer from severe psycholo-
gical disorders and more often experience their 
negative effects on quality of life [36−38]. 
Urrutia et al. [39] shows that comorbidities 
with asthma and anxiety and depression may 
affect control of disease symptoms. Anxiety and 
depression is also a factor which affects quality of 
life of these patients. In our study we also show 
the impact of depression and anxiety measured 
with HADS scale on the quality of life of asth-
matic patients. 
Pommer et al. [40] assert that mood disorders 
and anxiety are not determined exclusively by 
symptoms of disease or current health status, 
but also depend on individual personality traits. 
It should be remembered that in the presented 
study the majority of patients with controlled 
asthma were younger, better educated, professio-
nally active, and non−smoking. Such a profile of 
a patient may confirm that ability to cope with 
stress and mood disorders is conditioned by in-
dividual factors.
The outcomes of this study highlight the im-
portance of depression in asthma management. 
Even after controlling for symptom severity and 
anxiety, depression is associated with a decrease 
in general and asthma-specific quality of life, gre-
ater intake of corticosteroids, and marginally in-
creased hospitalization. Asthma patients should 
be included in routine screening for depression 
in hospital and primary care to identify those of 
them who need adjunctive behavioral therapy or 
psychiatric intervention.
Conclusions 
1. Asthma control significantly improves qu-
ality of life. 
2. Anxiety and depression are found in asthma 
patients, with higher severity observed in 
patients with uncontrolled asthma.
3. Female gender, the level of asthma control, 
asthma severity, smoking, as well as diagno-
ses of anxiety and depression are predictors 
of a significantly lower quality of life in 
asthma.
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